[1] Takehisa U and Masahiro F. Current status of intestinal transplantation[J]. Surg Today, 2010, 40(12):1112-1122.[2] Navdeep N, George M, Sarangarajan R, et al. Pediatric small bowel transplantation[J]. Semin Pediatr Surg, 2010,19(1): 68-77.[3] Berger M, Zeevi A, Farmer D G, et al. Immunologic challenges in small bowel transplantation[J].Am J Transplant, 2012, Suppl 4:S2-8[4] Trevizol A P, David A I, Dias F R, et al. Intestinal and multivisceral transplantation immunosuppression protocols-literature review [J]. Transplant Proc, 2012, 44(8):2455-2448.[5] Takahashi H, Kato T, Selvaqqi G, et al. Subclinical rejection in the initial postoperative period in small intestinal transplantation: a negative influence on graft survival[J]. Transplantation, 2007, 84(6): 689-696.[6] Mosmann T R, Cherwinski H, Bond M W, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins[J]. Immunol, 1986,136(7):2348-2357.[7] Liu Z, Fan H, Jiang S. CD4(+) T-cell substes in transplantation[J]. Immunol Rev,2013, 252(1):183-191[8] Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage[J]. Nat Med,2007, 13(2):139-147.[9] Moseley T A, Haudenschild D R, Rose L A, et al. Interleukin-17 family and IL-17 receptors[J]. Cytokine Growth Factor Rev, 2003,14(2):155-174.[10] Gaffen S L. Structure and signalling in the IL-17 receptor family[J]. Nat Rev Immunol,2009, 9(8): 556-567.[11] Aggarwal S, Gurney A L. IL-17: prototype member of an emerging cytokine family[J]. Leukoc Biol, 2002, 71(1): 1-8.[12] Afzali B, Lombardi G, Lechler R I, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease[J]. Clinical and Experimental Immunology, 2007, 148(1): 32-46.[13] Abadja F, Sarraj B, Ansari M J. Significance of T helper 17 immunity in transplantation[J]. Curr Opin Organ Transplant, 2012, 17(1):8-14.[14] Chadha R, Heidt S, Jones H D, et al. Th17: contributors to allograft rejection and a barrier to the induction of transplantationtolerance?[J]. Transplantation, 2011, 91(9):939-945.[15] Yuan X L, Jesus Paez-Cortez, Isabela Schmitt-Knosalla, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy[J]. J Exp Med, 2008,205(13): 3133-3144.[16] Kerem Atalar, Behdad Afzali, Graham Lord, et al. Relative roles of Th1 and Th17 effector cells in allograft rejection[J]. Current Opinion in Organ Transplantation, 2009,14(1):23-29.[17] Hans J P M, Koenen, Ruben L Smeets, Paul M Vink, et al. Human CD25high Foxp3pos regulatory T cells differentiate into IL-17-producing cells[J]. Blood, 2008,112(6):2340-2352.[18] Ruiz P, Kato T, Tzakis A. Current status of transplantation of the small intestine[J]. Transplantation,2007, 83(1):1-6.[19] Monchik G J, Russell P S. Transplantation of small bowel in the rat: technical and immunological considerations[J]. Surgery,1971, 70(5):693-702.[20] Kawabe T, Nakai T, Okuno K, et al. Small bowel transplantation in rats using a venous cuff technique[J]. Microsurgery,1998,18(5):344-347.[21] Fryer J P, Kim S, Wells C L, et al. Bacterial translocation in a large-animal model of small-bowel transplantation. Portal vs systemic venous drainage and effect of therolimus immunosuppression[J]. Arch-Surg, 1996,131(1):77-84.[22] Guo W H, Tian L, Dallmann M J, et al. Comparative study of allograft survival of heterotopie and orthotopic small bowel transplantation in rat[J]. Transplantation, 2003,75(11):1895-1897.[23] Chiu C J, Mcardle A H, Brown R, et al. Intestinal mucosal lesion in low flow states.I.A morphological,hemodynamic,and metabolic reappraisal[J]. Arch Surg, 1970,101(4):478-483.[24] Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage[J]. Nat Med, 2007, 13(2):139-147.[25] McGeachy M J, Bak-Jensen K S, Chen Y, et al. TGF-β and IL-6 drive the production of IL-17 and TGF-β by T cells and restrain TH-17 cell-mediated pathology[J]. Nat Immunol, 2007,8(12):1390-1397.[26] Veldhoen M, Hocking PJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory eytokine milieu supports de novo differentiation of IL-17-producing T cells[J]. Immunity, 2006,24(2):179-189.[27] Li L, Huang L, Vergis A, et al. IL-17 produced by neutrophils regulates IFN-γ–mediated neutrophil migration in mouse kidney ischemia-reperfusion injury[J]. J Clin Invest,2010,120(1): 331-342 |